Literature DB >> 33467191

Expression of Transcript Variants of PTGS1 and PTGS2 Genes among Patients with Chronic Rhinosinusitis with Nasal Polyps.

Wioletta Pietruszewska1, Wojciech Fendler2,3, Marta Podwysocka1, Adam J Białas4, Piotr Kuna5, Izabela Kupryś-Lipińska5, Maciej Borowiec6.   

Abstract

To date, there has been no reliable test to identify unfavorable course of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), especially in aspirin intolerant patients. The research aimed to analyze the expression of transcript variants of PTGS1 and PTGS2 genes in the pathobiology of the disease. The study was performed on 409 adult patients: 206 CRSwNP patients including 44 (21.36%) aspirin intolerant patients and 203 healthy volunteers in the control group. Transcript variants of the PTGS1 and PTGS2 genes named as follows: COX1.1 for NM_000962, COX1.2 for NM_080591, COX1.3 for NM_001271165.1, COX1.4 for NM_001271368.1, COX1.5 for NM_001271166.1, COX2.1 for NM_000963.3, COX2.2 for AY_151286 and COX2.3 for BQ_722004 were confirmed using direct sequencing and quantified using targeted qPCR. The coexistence of all examined transcript variants in the study and the control group and significant differences between both were found. In aspirin sensitive patients, the levels of COX1.2, COX1.3, COX1.4 and COX1.5 isoforms were higher compared to aspirin-tolerant patients. The severity of symptoms was bigger in patients with higher expressions of variants: COX1.1 (R with dCt = -0.134; p = 0.0490), COX1.3 (R = -0.1429; p = 0.0400) and COX1.5 (Rs = -0.1499; p = 0.032). The expression of COX1.1 (Rs = -0.098; p = 0.049) and COX1.5 (Rs = -0.141; p = 0.043) isoforms increased with polyposis advancement in endoscopy. With the CT extent of sinuses opacification, COX1.1 isoform also significantly increased (Rs = -0.163; p = 0.020). The isoforms COX1.3, COX1.4, COX1.5 and COX2.1 may promote milder CRSwNP course. On the contrary, the variants COX1.1, COX1.2 and COX2.2 may be involved in a more aggressive disease.

Entities:  

Keywords:  CRSwNP; NSAIDs; PTGS1 gene; PTGS2 gene; chronic rhinosinusitis with nasal polyps; cyclooxygenase-1; cyclooxygenase-2; non-steroidal anti-inflammatory drugs; prostaglandin-endoperoxide synthase 1 gene; prostaglandin-endoperoxide synthase 2 gene; transcript variant

Year:  2021        PMID: 33467191      PMCID: PMC7830232          DOI: 10.3390/diagnostics11010135

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  43 in total

Review 1.  Update on the molecular biology of nasal polyposis.

Authors:  Joel M Bernstein
Journal:  Otolaryngol Clin North Am       Date:  2005-12       Impact factor: 3.346

2.  Structure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandin endoperoxide H synthase-1.

Authors:  M G Malkowski; E D Thuresson; K M Lakkides; C J Rieke; R Micielli; W L Smith; R M Garavito
Journal:  J Biol Chem       Date:  2001-07-27       Impact factor: 5.157

3.  Prostaglandin E2 decrease in induced sputum of hypersensitive asthmatics during oral challenge with aspirin.

Authors:  Lucyna Mastalerz; Katarzyna E Tyrak; Maria Ignacak; Ewa Konduracka; Filip Mejza; Adam Ćmiel; Michał Buczek; Adrianna Kot; Krzysztof Oleś; Marek Sanak
Journal:  Allergy       Date:  2018-12-05       Impact factor: 13.146

Review 4.  Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.

Authors:  Whitney W Stevens; Robert P Schleimer
Journal:  Immunol Allergy Clin North Am       Date:  2016-09-13       Impact factor: 3.479

5.  COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.

Authors:  N V Chandrasekharan; Hu Dai; K Lamar Turepu Roos; Nathan K Evanson; Joshua Tomsik; Terry S Elton; Daniel L Simmons
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

6.  Genetic variation in cyclooxygenase 1: effects on response to aspirin.

Authors:  Marc K Halushka; Linda P Walker; Perry V Halushka
Journal:  Clin Pharmacol Ther       Date:  2003-01       Impact factor: 6.875

7.  Characterization of the human prostaglandin H synthase 1 gene (PTGS1): exclusion by genetic linkage analysis as a second modifier gene in familial thrombosis.

Authors:  B T Scott; S J Hasstedt; E G Bovill; P W Callas; J E Valliere; L Wang; K K Wu; G L Long
Journal:  Blood Coagul Fibrinolysis       Date:  2002-09       Impact factor: 1.276

8.  Analysis and quantitation of splicing variants of the TPA-inducible PGHS-1 mRNA in rat tracheal epithelial cells.

Authors:  J Kitzler; E Hill; R Hardman; N Reddy; R Philpot; T E Eling
Journal:  Arch Biochem Biophys       Date:  1995-02-01       Impact factor: 4.013

9.  Understanding the Role of Biofilms and Superantigens in Chronic Rhinosinusitis.

Authors:  Ivy W Maina; Neil N Patel; Noam A Cohen
Journal:  Curr Otorhinolaryngol Rep       Date:  2018-07-26

Review 10.  A summary of the new GINA strategy: a roadmap to asthma control.

Authors:  Helen K Reddel; Eric D Bateman; Allan Becker; Louis-Philippe Boulet; Alvaro A Cruz; Jeffrey M Drazen; Tari Haahtela; Suzanne S Hurd; Hiromasa Inoue; Johan C de Jongste; Robert F Lemanske; Mark L Levy; Paul M O'Byrne; Pierluigi Paggiaro; Soren E Pedersen; Emilio Pizzichini; Manuel Soto-Quiroz; Stanley J Szefler; Gary W K Wong; J Mark FitzGerald
Journal:  Eur Respir J       Date:  2015-07-23       Impact factor: 16.671

View more
  3 in total

1.  Serum IL-5, POSTN and IL-33 levels in chronic rhinosinusitis with nasal polyposis correlate with clinical severity.

Authors:  Hanna Zielińska-Bliźniewska; Milena Paprocka-Zjawiona; Anna Merecz-Sadowska; Radosław Zajdel; Katarzyna Bliźniewska-Kowalska; Katarzyna Malinowska
Journal:  BMC Immunol       Date:  2022-06-25       Impact factor: 3.594

2.  A New Strategy for the Rapid Identification and Validation of the Direct Targets of Aconitine-Induced Cardiotoxicity.

Authors:  Jinxia Wei; Simiao Fan; Hongxin Yu; Lexin Shu; Yubo Li
Journal:  Drug Des Devel Ther       Date:  2021-11-13       Impact factor: 4.162

3.  Network pharmacology-based analysis of the mechanism of Saposhnikovia divaricata for the treatment of type I allergy.

Authors:  Xiangsheng Li; Hui Li; Tingting Wang; Yang Zhao; Yuxin Shao; Yizhao Sun; Yanfen Zhang; Zhongcheng Liu
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.